#ESMO26: In phase III trials, izalontamab brengitecan (#BispecificADC targeting EGFR and #HER3) and ruzaltatug rezetecan (#ADC targeting HER3) showed significant efficacy in patien

ESMO - Eur. Oncology· @myESMO · X·2026-10-26 17:12· 5 小时前评分45

正文 · 原文

#ESMO26: In phase III trials, izalontamab brengitecan (#BispecificADC targeting EGFR and #HER3) and ruzaltatug rezetecan (#ADC targeting HER3) showed significant efficacy in patients with locally advanced or #metastatic #EGFRmutant #NSCLC

🔗 https://ow.ly/qpgc5100JU5

#InsightsbyESMO

75 浏览 · 1 赞 · 1 转发 · 0 回复

会议摘要

2575PNCT06838273 NCT06838273 NCT06838273按 NSCLC, locally advanced 对上

Phase II study of izalontamab brengitecan (Iza-bren) plus osimertinib in patients with EGFR mutant locally advanced or metastatic non-small cell lung cancer (NSCLC)

https://esmocongress.esmo.org

LBA50按 Proffered paper 1: Breast cancer, early and advanced stage 对上

PANKU-Breast01: Randomized phase III study of izalontamab brengitecan (iza-bren) in previously treated unresectable locally advanced or metastatic (LA/M) hormone receptor-positive/HER2-negative (HR+/HER2-) breast cancer (BC)

https://esmocongress.esmo.org

来源：ESMO - Eur. Oncology · x.com